Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDT | P30046 | 2/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.46 |
| ▸ | CCR1 | P32246 | 10/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12853550 | 0.91 | DDT (0.51) | DDTRIPK1CCR1EPHX2ADRB2 | |
| SCHEMBL12853541 | 0.91 | DDT (0.50) | DDTCCR1EPHX2ADRB2ELANE | |
| SCHEMBL8204104 | 0.91 | DDT (0.54) | DDTCCR1EPHX2ADRB2ELANE | |
| SCHEMBL12853540 | 0.90 | DDT (0.50) | DDTCCR1EPHX2ADRB2ELANE | |
| SCHEMBL3116577 | 0.89 | DDT (0.49) | DDTCCR1EPHX2ADRB2ELANE | |
| SCHEMBL8208208 | 0.85 | DDT (0.53) | DDTCCR1EPHX2ADRB2ELANE | |
| SCHEMBL8212310 | 0.85 | DDT (0.53) | DDTCCR1EPHX2ADRB2ELANE | |
| SCHEMBL12853297 | 0.84 | DDT (0.53) | DDTCCR1EPHX2ADRB2ELANE | |
| SCHEMBL8213673 | 0.84 | DDT (0.51) | DDTCCR1EPHX2ADRB2ELANE | |
| SCHEMBL13246860 | 0.83 | DDT (0.50) | DDTCCR1EPHX2ADRB2ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2132178-B1 | JNK INHIBITORS | MERCK SHARP & DOHME (US) | 2015-08-19 | — | — | EP | disclosed |
| US-8278337-B2 | Substituted pyridines that are JNK inhibitors | MERCK SHARP & DOHME (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278337-B2 | Substituted pyridines that are JNK inhibitors | MERCK SHARP & DOHME (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100179141-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-07-15 | — | — | US | disclosed |
| US-20100179141-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179141-A1 | NOVEL JNK INHIBITORS | MAPK1, MAPKAPK5, MAPK15 | DDT 4423/4885RIPK1 913/4885CCR1 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.